That makes it seem like they will be continuing with the ACTIV trial for awhile longer. I'm not sure if that is good news or bad news. It'll be good for the BLA. But the downside is that lenz probably isn't getting the EUA anytime soon since they aren't going to simultaneously have a trial with patients getting a placebo when a patient could get the drug with the EUA. Maybe this explains the Chappell sells.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.